|
|
||||||||
Original Research Communications |
| ABSTRACT |
|---|
|
|
|---|
Objective: We studied whether maternal zinc supplementation improved the zinc status of mothers and neonates participating in a supplementation trial in a shantytown in Lima, Peru.
Design: Beginning at gestation week 1024, 1295 mothers were randomly assigned to receive prenatal supplements containing 60 mg Fe and 250 µg folate, with or without 15 mg Zn. Venous blood and urine samples were collected at enrollment, at gestation week 2830, and at gestation week 3738. At birth, a sample of cord vein blood was collected. We measured serum zinc concentrations in 538 women, urinary zinc concentrations in 521 women, and cord zinc concentrations in 252 neonates.
Results: At 2830 and 3738 wk, mothers receiving zinc supplements had higher serum zinc concentrations than mothers who did not receive zinc (8.8 ± 1.9 compared with 8.4 ± 1.5 µmol/L and 8.6 ± 1.5 compared with 8.3 ± 1.4 µmol/L, respectively). Urinary zinc concentrations were also higher in mothers who received supplemental zinc (P < 0.05). After adjustment for covariates and confounding factors, neonates of mothers receiving zinc supplements had higher cord zinc concentrations than neonates of mothers who did not receive zinc (12.7 ± 2.3 compared with 12.1 ± 2.1 µmol/L). Despite supplementation, maternal and neonatal zinc concentrations remained lower than values reported for well-nourished populations.
Conclusion: Adding zinc to prenatal iron and folate tablets improved maternal and neonatal zinc status, but higher doses of zinc are likely needed to further improve maternal and neonatal zinc status in this population.
Key Words: Maternal zinc deficiency pregnancy zinc status supplementation iron folate women neonates Peru
| INTRODUCTION |
|---|
|
|
|---|
Pregnant women are also at risk of other micronutrient deficiencies and there is interest in the public health community in adding other nutrients to prenatal supplements taken by pregnant women worldwide. In particular, there is growing concern that maternal zinc deficiency may be widespread (3, 4). Adding zinc to prenatal iron and folate tablets, however, may be problematic. Iron and zinc are known to compete for absorption (5) and iron supplements may themselves impair maternal zinc status (69). Although less studied, concern that folic acid supplementation may impair zinc absorption has also been raised (9, 10).
The results of the several zinc supplementation studies of pregnant women that have been conducted in developed countries have been mixed (1114). In 2 studies, zinc was incorporated directly into the prenatal supplements (12, 14); of these studies, only one reported significant improvements in maternal serum zinc concentrations during pregnancy in zinc-supplemented women (14). The women in these studies (1114), however, had higher intakes of zinc and iron than would be true for most women in developing countries. Because maternal needs for both zinc and iron during pregnancy appear to influence zinc absorption and metabolism (15), the relevance of these findings for women in developing countries is not clear.
As part of a randomized trial of maternal zinc supplementation and pregnancy outcome and maternal and infant health, Peruvian women were randomly assigned to receive prenatal iron and folate supplements with or without zinc. Because Peruvian guidelines indicate universal prenatal iron supplementation, we could not directly assess the effect of iron supplementation on zinc status; however, we could examine whether adding zinc to prenatal iron and folate tablets improved the zinc status of these women during pregnancy and of their neonates at delivery.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
Women were considered eligible for the study if they had a low-risk pregnancy (uncomplicated and eligible for vaginal delivery), were carrying a singleton fetus, and had lived in coastal Peru for
6 mo before becoming pregnant. The women gave their signed consent to participate after the protocol was fully explained to them. The study protocol was approved by the institutional review boards of the Instituto de Investigación Nutricional (IIN) and The Johns Hopkins School of Hygiene and Public Health.
On entry into prenatal care between gestation weeks 10 and 24, women were randomly assigned by parity (nullipara or multipara) and week of gestation at enrollment (<17 or
17 wk) strata to receive daily supplements containing 60 mg Fe (as ferrous sulfate) and 250 µg folate with or without an additional 15 mg Zn (as zinc sulfate). Per Peruvian guidelines, women were asked to take one pill daily midmorning with a vitamin Ccontaining drink or water. Supplementation began at gestation week 1024 and continued until 4 wk postpartum. The supplements were produced by a local pharmaceutical company (Instituto Quimioterápico, SA, Lima, Peru) in coded blister packages. To verify the formulation of the supplements and the integrity of the coding scheme, samples of each supplement type were analyzed by the IIN laboratory 2 times during the study. Despite this, the investigators remained blinded as to the coding scheme until data analyses for this paper were almost complete.
At enrollment, sociodemographic information was collected by interview. Duration of pregnancy was calculated based on maternal reporting of date of last menses, as well as by clinical indications of pregnancy duration at enrollment, and a best estimate of gestational age was determined. Women were followed up monthly (or as necessary) by the hospital staff as well as by the project obstetrician. Maternal anthropometric measures and venous blood samples for monitoring concentrations of serum zinc, serum ferritin, and hemoglobin were taken at enrollment, at gestation week 2830, and at gestation week 3738. At each time point, a urine sample was also collected to assess urinary zinc concentrations. At birth, a sample of cord vein blood was taken to determine newborn serum zinc concentrations. Compliance with the supplementation was monitored by pill counts and was checked biweekly by health care workers who interviewed the women in their homes. For these analyses, we considered compliance as the number of pills provided to each mother for the number of days she was in the study during pregnancy. Infants were weighed at birth by hospital personnel and crown-heel length and various circumferences and skinfold thicknesses were measured on day 1 by project personnel.
Blood and urine samples were collected from women in a fasted state between 0800 and 1000. Blood samples were centrifuged immediately at room temperature for 5 min at 30003500 rpm, frozen at -20°C, and then transported on ice during a 45-min drive to the IIN laboratory. At IIN, serum and urinary zinc concentrations were measured by atomic absorption spectrophotometry (model 3100; Perkin-Elmer, Norwalk, CT) and serum ferritin was measured in duplicate by an enzyme-linked immunosorbent assay with reagents purchased from DAKO (Santa Barbara, CA). Bovine liver from the National Institute of Standards and Technology (Gaithersburg, MD) and ferritin controls (Diagnostic Products Corporation, Los Angeles) were used as standards and values were within expected ranges. Hemoglobin concentrations were measured at the hospital by the cyanomethemoglobin method under the supervision of IIN laboratory staff.
It was not feasible to collect 24-h urine samples for all women to estimate urinary zinc excretion, or to reduce some of the random variation in excretion by adjusting for creatinine. Zlotkin and Casselman (17) showed a strong correlation (r = 0.87) between urinary zinc excretion estimated from a single urine sample and estimates of total urinary zinc excretion over a 24-h period and estimated that creatinine adjustment reduces the variance in urinary zinc excretion by 24%. Thus, our data on urinary zinc excretion from single urine samples should provide accurate (unbiased) estimates of the mean or median of the distributions of total urinary zinc excretion for comparison by supplement type, but inflated estimates of the variances of the distributions.
A total of 1295 women were enrolled in the supplementation trial. We attempted to collect biological samples from all women and neonates, but cord samples could be collected at only 70% of the births at the project hospital and costs prohibited analyses of all blood and urine samples. Therefore, to examine the effect of zinc supplementation on indicators of zinc status, we decided to measure maternal serum zinc and urinary zinc concentrations in a subsample of
500 women with serial blood and urine samples. This decision was made after
1000 serum samples (from all 3 time points) had been analyzed. Therefore, women whose samples had already been analyzed were included in this subsample; if samples could not be collected at all 3 time points for women with
1 sample already analyzed (for example, if they gave birth before gestation week 37), the women were replaced in the cohort. The goal was to include women in the subsample throughout the study enrollment period; however, because the sample size of 500 women was reached before the end of enrollment, few of the final 200 women enrolled in the study were included in the subsample.
Ultimately, 3 serum zinc determinations were available for 538 women (270 and 268 per supplementation group), representing 42% of all women enrolled in the study, 49% of the first 1100 women enrolled in the study, and 60% of all women delivering after gestation week 38. For 521 of these women (97%), serial urinary zinc determinations (256 and 265 per supplementation group) were also available. Overall, 363 determinations of cord zinc concentration were made, 256 of them were in infants born to women in this cohort (129 and 127 per supplementation group). For consistency, we present the data on 252 (98%) of the infants born to women with serial zinc determinations for whom anthropometric data at birth were also available.
Baseline characteristics in the supplementation groups were compared by t tests or chi-square analyses to assess comparability. Maternal serum zinc concentrations at each of the 3 time points and cord serum zinc concentrations in the newborns were compared by t tests. Between-group comparisons of urinary zinc concentrations were also performed by t tests, after the distributions were normalized by using a cube-root transformation. Analysis of variance techniques were then used to estimate the effects of zinc supplementation on maternal serum zinc and (transformed) urinary zinc concentrations during pregnancy and to estimate supplementation effects on neonatal zinc status, adjusted for covariates and potentially confounding factors (18). For presentation, the values for the adjusted median and ± 1 SD of urinary zinc concentrations were transformed to their original units (µmol/L). The effect of zinc supplementation on maternal serum and urinary zinc concentrations was also estimated after adjustment for initial zinc concentration (at gestation week 1024). Furthermore, we investigated whether the effect of maternal zinc supplementation varied depending on selected maternal characteristics including initial zinc concentration. To characterize the magnitude of the change in maternal and newborn zinc status in response to zinc supplementation, we calculated the responsiveness of each indicator, which is the difference in the postsupplementation means (or medians) of the indicator divided by the pooled SD (19, 20). Responsiveness can also be calculated as the response per unit dose of the supplement to compare the responsiveness of each indicator across different levels of supplementation (19). Statistical significance was defined as P < 0.05 and data analyses were performed with SAS (SAS Institute Inc, Cary, NC).
| RESULTS |
|---|
|
|
|---|
|
|
|
The characteristics of 252 of the infants born to the women studied are presented in Table 3
. No significant differences in infant size or gestational age at birth by supplement type were found. The cord vein serum zinc concentrations of the newborns are compared by supplement type in Table 4
, before and after adjustment for covariates and potentially confounding factors. The difference in cord zinc concentration by type of prenatal supplement was only marginally significant initially, but became significant after adjustment for maternal age and parity, in-home electricity, and infant birth weight and sex. As shown, adjustment for these factors did not greatly influence the estimated difference in mean cord zinc concentration by supplement type, but rather reduced the variance in cord zinc concentration around each mean. This is because cord zinc concentration was positively associated with birth weight, male sex, and maternal parity, and each contributed substantially to the variability in observed cord zinc concentrations in neonates. The responsiveness of cord zinc concentration to maternal zinc supplementation was 0.22 SD before adjustment and 0.27 SD after adjustment. Neonatal zinc concentrations responded 0.03 µmol/L per mg supplemental Zn/d provided to the mother.
|
|
| DISCUSSION |
|---|
|
|
|---|
The responsiveness of the indicators of maternal and neonatal zinc status to zinc supplementation indicated shifts in the distributions of 0.160.21 SD for maternal urinary zinc concentrations, 0.210.23 SD for maternal serum zinc concentrations, and 0.230.27 SD for newborn cord zinc concentrations. In other zinc supplementation studies in which women were supplemented with 1530 mg elemental Zn/d (1114), the responsiveness of maternal plasma or serum zinc concentrations to zinc supplementation varied between 0.0 and 0.89 SD (Table 5
). Although slight, there was some evidence of a positive association between responsiveness and dosage in these studies; supplementation-associated shifts in plasma or serum zinc concentrations were 00.1, 0.16, 0.110.35, and 0.120.89 SD for daily supplements containing 15, 20, 25, and 30 mg Zn, respectively. The responsiveness of maternal serum zinc concentrations in our study of Peruvian women was within the range of estimates of responsiveness calculated from the literature, but the magnitude was similar to estimates from studies in which higher doses of zinc were provided. When considered per mg supplemental Zn/d (Table 5
), the data across studies become more consistent, suggesting that maternal serum zinc concentrations respond 0.000.10 µmol/L for each mg supplemental Zn/d provided during pregnancy.
|
The absolute difference in cord zinc concentration by supplement type was nearly 2 times that observed in maternal serum late in pregnancy, and the cord zinc concentrations of neonates born to zinc-supplemented mothers were somewhat higher (P = 0.08) after adjustment for maternal serum zinc concentrations late in pregnancy. Thus, the fetuses may have benefited more from zinc supplementation than the mothers. However, both maternal and cord zinc concentrations increased by
5% in response to supplementation and, regardless of supplement type, cord zinc concentrations were
50% higher than maternal serum zinc concentrations during late pregnancy, a finding consistent with reports from both well-nourished and zinc-deficient populations (14, 24). Thus, although the fetuses may have benefited slightly more than the mothers from prenatal zinc supplementation, greater improvement in maternal zinc status before or during pregnancy is likely required to bring about greater improvements in fetal zinc status as assessed by cord zinc concentrations.
Maternal serum zinc concentrations declined more rapidly in our population than in more zinc-replete populations (Figure 1
). Congruent with this, maternal urinary zinc concentrations were uniformly low during pregnancy, declined at 2830 wk, and then increased only slightly at 3738 wk. This pattern is in contrast with the progressive increases in urinary zinc excretion that typically occur during pregnancy, particularly during the third trimester (11, 15). Moreover, the cord zinc concentrations were similar to values reported for Zairian newborns (24), but much lower than typical cord zinc concentrations of 1516 µmol/L (25). These findings suggest continued zinc deficiency in these women and their neonates despite daily prenatal zinc supplementation with 15 mg Zn from gestation week 1024 until delivery.
It is possible that some of the differences in maternal serum and urinary zinc concentrations between our study and others reported in the literature (Figure 1
) resulted from iron and folate supplementation rather than zinc deficiency per se. Because all women in this project received daily iron and folate supplements, we cannot address this possibility. However, the women participating in most of the studies reported in the literature of maternal zinc status during pregnancy also consumed prenatal iron supplements, some of which also contained up to 1 mg folate/d (1114).
The primary limitation of our analysis is that we did not assess the effect of prenatal zinc supplementation in all participants or in a representative subsample of participants and their newborns. Instead, we analyzed samples from a subsample of 538 women who provided 3 serum samples during their pregnancy and cord zinc concentrations in a subsample of 252 of their neonates. Because of the sampling scheme, it is clear that women who were able to provide 3 samples had longer pregnancies than women not providing 3 samples. Furthermore, the analysis consisted of women who participated in the project earlier as opposed to near the end because we stopped analyzing serum samples when the number of women with 3 analyzed samples reached
500. To examine potential selection bias, we compared the characteristics of eligible women (among the first 1100 participants giving birth after 38 completed weeks of gestation) by whether they contributed serum samples to the analysis. These analyses revealed no significant differences by supplement type, but women whose serum samples were included in the analysis were more likely to be older, of greater parity, more educated, and less likely to have in-home electricity. They were also more likely to have given birth in the project hospital, perhaps indicating lower obstetric risk. Maternal age was negatively associated with serum zinc concentrations at enrollment and differences by supplement type in age and in-home electricity among participants were noted at enrollment. In sum, it appears that the women described here were somewhat better off than eligible women whose sera were not analyzed, and that eligible women were somewhat better off than the rest of the project participants. Despite this, we found no evidence that such differences were related to supplement type, and during analyses we adjusted for maternal age and in-home electricity. Thus, the zinc status of the sample and the effect of supplementation on zinc status described here can likely be generalized to all project participants.
Despite this limitation, we showed the efficacy of adding zinc to prenatal iron and folate tablets to improve maternal and neonatal zinc status, and that maternal serum and urinary zinc concentrations as well as cord zinc concentrations at birth are responsive to prenatal zinc supplementation. The data, however, indicate continued maternal and neonatal zinc deficiency in this population and suggest that higher doses of zinc should be added to the prenatal supplements. Future studies should investigate the effect of higher doses of zinc incorporated into prenatal supplements on maternal and neonatal zinc status in this and similar populations.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 Presented in part at Experimental Biology `97 in New Orleans, April 9, 1997: Caulfield LE, Zavaleta N. Serum zinc concentrations in pregnant Peruvian women receiving prenatal iron and zinc supplements. FASEB J 1997;11:A654 (abstr).
3 Supported by DAN-5116-A-00-8051-00 and HRN-A-00-97-00015-00, cooperative agreements between USAID/OHN and The Johns Hopkins University.
4 Address reprint requests to LE Caulfield, Center for Human Nutrition, Department of International Health, The Johns Hopkins School of Hygiene and Public Health, Room W2041, 615 North Wolfe Street, Baltimore, MD 21205. E-mail: lcaulfie{at}jhsph.edu.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. L Iannotti, N. Zavaleta, Z. Leon, A. H Shankar, and L. E Caulfield Maternal zinc supplementation and growth in Peruvian infants Am. J. Clinical Nutrition, July 1, 2008; 88(1): 154 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Walker, K. Kordas, R. J Stoltzfus, and R. E Black Interactive effects of iron and zinc on biochemical and functional outcomes in supplementation trials Am. J. Clinical Nutrition, July 1, 2005; 82(1): 5 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M Donangelo, C. L Vargas Zapata, L. R Woodhouse, D. M Shames, R. Mukherjea, and J. C King Zinc absorption and kinetics during pregnancy and lactation in Brazilian women Am. J. Clinical Nutrition, July 1, 2005; 82(1): 118 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Merialdi, L. E Caulfield, N. Zavaleta, A. Figueroa, K. A Costigan, F. Dominici, and J. A Dipietro Randomized controlled trial of prenatal zinc supplementation and fetal bone growth Am. J. Clinical Nutrition, May 1, 2004; 79(5): 826 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Creed-Kanashiro, R. M. Bartolini, M. N. Fukumoto, T. G. Uribe, R. C. Robert, and M. E. Bentley Formative Research to Develop a Nutrition Education Intervention to Improve Dietary Iron Intake among Women and Adolescent Girls through Community Kitchens in Lima, Peru J. Nutr., November 1, 2003; 133(11): 3987S - 3991. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. M. Osendarp, C. E. West, and R. E. Black The Need for Maternal Zinc Supplementation in Developing Countries: An Unresolved Issue J. Nutr., March 1, 2003; 133(3): 817S - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B Stephensen, L. M. Franchi, H. Hernandez, M. Campos, A. Colarossi, R. H Gilman, and J. O Alvarez Assessment of vitamin A status with the relative-dose-response test in Peruvian children recovering from pneumonia Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1351 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. O. OBrien, N. Zavaleta, L. E. Caulfield, J. Wen, and S. A. Abrams Prenatal Iron Supplements Impair Zinc Absorption in Pregnant Peruvian Women J. Nutr., September 1, 2000; 130(9): 2251 - 2255. [Abstract] [Full Text] |
||||
![]() |
O. A Ladipo Nutrition in pregnancy: mineral and vitamin supplements Am. J. Clinical Nutrition, July 1, 2000; 72(1): 280S - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hambidge Human Zinc Deficiency J. Nutr., May 1, 2000; 130(5): 1344S - 1349. [Abstract] [Full Text] |
||||
![]() |
N. F. Krebs Overview of Zinc Absorption and Excretion in the Human Gastrointestinal Tract J. Nutr., May 1, 2000; 130(5): 1374S - 1377. [Abstract] [Full Text] |
||||
![]() |
N. Zavaleta, L. E Caulfield, and T. Garcia Changes in iron status during pregnancy in Peruvian women receiving prenatal iron and folic acid supplements with or without zinc Am. J. Clinical Nutrition, April 1, 2000; 71(4): 956 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Caulfield, N. Zavaleta, A. Figueroa, and Z. Leon Maternal Zinc Supplementation Does Not Affect Size at Birth or Pregnancy Duration in Peru J. Nutr., August 1, 1999; 129(8): 1563 - 1568. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |